Comparative Pharmacology
Head-to-head clinical analysis: PHOSLYRA versus SEVELAMER HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHOSLYRA versus SEVELAMER HYDROCHLORIDE.
PHOSLYRA vs SEVELAMER HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phoslyra (calcium acetate) binds dietary phosphate in the gastrointestinal tract, forming insoluble calcium phosphate complexes that are excreted in the feces, thereby reducing serum phosphate levels.
Sevelamer hydrochloride is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, preventing its absorption and thereby reducing serum phosphate levels.
1330 mg (one caplet) orally three times daily with meals, titrated to achieve serum phosphorus within target range.
Initial dose: 800-1600 mg orally three times daily with meals. Titrate by 800 mg per meal at 2-week intervals based on serum phosphorus levels. Maintenance: typically 2.4-4.8 g/day divided with meals.
None Documented
None Documented
Not applicable; Phoslyra (calcium acetate) is not absorbed systemically; local effect in GI tract.
Not applicable; sevelamer is not absorbed. The polymer acts locally in the gastrointestinal tract and does not have a measurable plasma half-life.
Renal 100% as unchanged drug, no biliary or fecal elimination.
Sevelamer hydrochloride is not absorbed systemically; it is eliminated entirely in the feces as the unchanged polymer. No renal or biliary elimination occurs.
Category C
Category A/B
Phosphate Binder
Phosphate Binder